Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ganitumab + gemcitabine
- Development stage
- Unknown
- Lead developer
- Amgen
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
**Ganitumab + gemcitabine** is an investigational combination of two anti-cancer agents used in clinical trials for advanced solid tumors, notably metastatic pancreatic cancer. **Ganitumab** is a fully human monoclonal antibody antagonist targeting the insulin-like growth factor 1 receptor (IGF1R), inhibiting tumor cell growth and survival. **Gemcitabine** is a nucleoside analog that interferes with DNA synthesis, causing cytotoxicity in proliferating cancer cells. Clinical studies show this combination yields tolerable toxicity and trends toward improved survival in patients with metastatic pancreatic adenocarcinoma[1][3][5].
- Brand names
- ganitumab + gemcitabine
- Other names
- ganitumab and gemcitabine
02
Targets
IGF-1R (Insulin-like growth factor 1 receptor)
Beyond the preview
Go deeper on ganitumab + gemcitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ganitumab + gemcitabine.